ZA200802813B - Antitumor agent - Google Patents

Antitumor agent

Info

Publication number
ZA200802813B
ZA200802813B ZA200802813A ZA200802813A ZA200802813B ZA 200802813 B ZA200802813 B ZA 200802813B ZA 200802813 A ZA200802813 A ZA 200802813A ZA 200802813 A ZA200802813 A ZA 200802813A ZA 200802813 B ZA200802813 B ZA 200802813B
Authority
ZA
South Africa
Prior art keywords
antitumor agent
antitumor
agent
Prior art date
Application number
ZA200802813A
Other languages
English (en)
Inventor
Yazawa Shin
Nishimura Touyou
Nakagawa Takashi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of ZA200802813B publication Critical patent/ZA200802813B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
ZA200802813A 2005-09-02 2006-09-01 Antitumor agent ZA200802813B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005255517 2005-09-02

Publications (1)

Publication Number Publication Date
ZA200802813B true ZA200802813B (en) 2009-10-28

Family

ID=37808952

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802813A ZA200802813B (en) 2005-09-02 2006-09-01 Antitumor agent

Country Status (24)

Country Link
US (1) US7968116B2 (zh)
EP (1) EP1921086B1 (zh)
JP (1) JP5011113B2 (zh)
KR (1) KR101292539B1 (zh)
CN (1) CN101253192B (zh)
AR (1) AR057793A1 (zh)
AU (1) AU2006285678B2 (zh)
BR (1) BRPI0615196A2 (zh)
CA (1) CA2621377C (zh)
CY (1) CY1115196T1 (zh)
DK (1) DK1921086T3 (zh)
ES (1) ES2459767T3 (zh)
HK (1) HK1115140A1 (zh)
HR (1) HRP20140439T1 (zh)
IL (1) IL189752A (zh)
MY (1) MY155903A (zh)
NO (1) NO20081125L (zh)
PL (1) PL1921086T3 (zh)
PT (1) PT1921086E (zh)
RU (1) RU2410389C2 (zh)
SI (1) SI1921086T1 (zh)
TW (1) TWI373473B (zh)
WO (1) WO2007026869A1 (zh)
ZA (1) ZA200802813B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300722B6 (cs) * 2006-09-27 2009-07-22 Univerzita Karlova v Praze, Prírodovedecká fakulta Zpusob prípravy inkluzního komplexu pentacyklických a tetracyklických terpenoidu a farmaceutického prostredku obsahujícího tento inkluzní komplex, inkluzní komplex pentacyklického nebo tetracyklického terpenoidu a farmaceutický prostredek obsahující
TWI492759B (zh) * 2008-03-05 2015-07-21 Otsuka Pharma Co Ltd 膽甾烷醇衍生物之併用用途
KR20110122682A (ko) 2009-03-04 2011-11-10 오츠카 세이야쿠 가부시키가이샤 콜레스탄올 유도체의 병용 용도
US20120058178A1 (en) 2009-03-30 2012-03-08 Eisai R&D Management Co., Ltd. Liposome Composition
JP5622719B2 (ja) 2009-03-30 2014-11-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
US9592229B2 (en) 2012-03-02 2017-03-14 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
WO2013134407A2 (en) 2012-03-06 2013-09-12 The Board Of Trustees Of The University Of Illinois Procaspase 3 activation by combination therapy
DK2822546T3 (en) * 2012-03-06 2017-10-30 The Board Of Trustees Of The Univ Of Illionis PROCASPACE COMBINATION THERAPY FOR CANCER TREATMENT
CN103349948B (zh) * 2013-06-21 2015-05-27 江南大学 一种植物甾烷醇微胶囊化方法
RU2544455C1 (ru) * 2013-12-30 2015-03-20 Федеральное государственное бюджетное учреждение "Государственный научный центр колопроктологии" Министерства здравоохранения Российской Федерации Способ закрытой геморроидэктомии с гофрирующим швом
CN105753923B (zh) * 2014-12-17 2017-09-29 富力 20(R)‑人参皂苷Rg3多酰基化衍生物、制备及其应用
MX2020004991A (es) 2017-11-17 2022-02-10 Univ Illinois Terapia oncológica mediante la degradación de la señalización dual de mek.
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572300A (en) 1980-06-09 1982-01-07 Tetsuo Suami Novel nitrosourea derivative
SE8902235D0 (sv) * 1989-06-20 1989-06-20 Haessle Ab Novel cyclodextrin inclusion complexes
JP4105258B2 (ja) * 1997-08-19 2008-06-25 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
JPH11160592A (ja) 1997-11-28 1999-06-18 Hitachi Cable Ltd 光ファイバケーブル用スペーサ
JP4351314B2 (ja) 1998-12-24 2009-10-28 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
US7465753B2 (en) 2003-07-17 2008-12-16 Otsuka Pharmaceutical Co., Ltd. Glycoside-containing liposome
EP1709063B1 (en) * 2003-12-18 2008-01-23 Unibioscreen S.A. Glycosylated steroid derivatives with anti-migratory activity
JP2005225822A (ja) * 2004-02-13 2005-08-25 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤
KR100603814B1 (ko) * 2004-03-11 2006-07-25 바이오스펙트럼 주식회사 나노리포좀 조성물

Also Published As

Publication number Publication date
CA2621377A1 (en) 2007-03-08
NO20081125L (no) 2008-05-16
US7968116B2 (en) 2011-06-28
DK1921086T3 (da) 2014-05-05
AU2006285678A1 (en) 2007-03-08
TW200738744A (en) 2007-10-16
RU2410389C2 (ru) 2011-01-27
TWI373473B (en) 2012-10-01
PL1921086T3 (pl) 2014-09-30
RU2008112676A (ru) 2009-10-10
IL189752A (en) 2013-07-31
HRP20140439T1 (hr) 2014-06-20
CN101253192A (zh) 2008-08-27
AR057793A1 (es) 2007-12-19
CN101253192B (zh) 2011-05-04
EP1921086B1 (en) 2014-04-16
EP1921086A1 (en) 2008-05-14
BRPI0615196A2 (pt) 2011-05-10
JP5011113B2 (ja) 2012-08-29
AU2006285678B2 (en) 2012-01-19
SI1921086T1 (sl) 2014-05-30
US20100292176A1 (en) 2010-11-18
ES2459767T3 (es) 2014-05-12
CA2621377C (en) 2013-10-22
KR101292539B1 (ko) 2013-08-20
HK1115140A1 (en) 2008-11-21
PT1921086E (pt) 2014-04-29
EP1921086A4 (en) 2012-07-25
MY155903A (en) 2015-12-15
KR20080043838A (ko) 2008-05-19
CY1115196T1 (el) 2017-01-04
JPWO2007026869A1 (ja) 2009-03-12
WO2007026869A1 (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
PL2175273T3 (pl) Środek nadający kokumi
EP2062596A4 (en) ANTI-TUMOR AGENT
ZA200802813B (en) Antitumor agent
IL184788A0 (en) Quinoxaline derivatives as antitumor agents
EP2239264A4 (en) ANTITUMOR AGENT
EP1950309A4 (en) ALBUMIN DENATURING AGENCY
EP1852112A4 (en) ANTITUMOR AGENTS
HK1116064A1 (en) Antitumor agent
GB2440699B (en) Combination dolly-pallet
EP1719527A4 (en) ANTITUMORAL MEDIUM
EP1852499A4 (en) AGENT PROMOTING NEUROTISATION
EP1927347A4 (en) MEANS TO REDUCE BITTERNESS
EP1889660A4 (en) OZONE-GROWING AGENT
GB0523041D0 (en) Combination
HK1156505A1 (en) Anti-allergic agent
GB0523040D0 (en) Combination
EP1754473A4 (en) ANTITUMOR AGENT
EP1865313A4 (en) OPTICAL ISOMER SEPARATION AGENT
EP1867339A4 (en) ANTIVIRAL MEDIUM
GB0514758D0 (en) Anti-cancer agent
AU3401P (en) Archise Arctotis fastuosa
AU3621P (en) Scacover Scaevola aemula
AU3393P (en) Breakwell xTriticosecale
AU3292P (en) DP303 Dianella prunina
GB0508237D0 (en) Combination